Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Counsyl | RCV000667351 | SCV000791785 | likely pathogenic | Bardet-Biedl syndrome 2 | 2017-05-23 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000667351 | SCV004214041 | pathogenic | Bardet-Biedl syndrome 2 | 2023-03-28 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV003523006 | SCV004297729 | pathogenic | Bardet-Biedl syndrome | 2022-12-29 | criteria provided, single submitter | clinical testing | Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. This sequence change affects a donor splice site in intron 3 of the BBS2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in BBS2 are known to be pathogenic (PMID: 11285252, 20177705, 24608809, 26518167). This variant is not present in population databases (gnomAD no frequency). Disruption of this splice site has been observed in individual(s) with clinical features of retinal dystrophy and Bardet-Biedl syndrome (PMID: 27032803). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. ClinVar contains an entry for this variant (Variation ID: 552136). For these reasons, this variant has been classified as Pathogenic. |